secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001628280-22-028908
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma Q3 net loss $70.3M; GSK ends collaboration; LYL797 data delayed to H1 2024
--------------------------------------------------------------------------------

- Net loss $70.3M vs $48.9M YoY; non-GAAP net loss $43.7M vs $35.7M.
- Cash $750.7M as of Sep 30, 2022; funding extends into 2026.
- GSK terminates NY-ESO-1 programs LYL132/LYL331 effective Dec 24, 2022; not due to safety/efficacy.
- IND cleared for LYL845 TIL therapy; initial data expected 2024.
- LYL797 enrollment slower; initial data now expected first half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/0001628280-22-028908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/lyel-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer